CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

219 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerCetuximab,Encorafenib,BinimetinibScott Kopetz, 2019, Gastrointestinal Cancers Symposium, Abstract 688
BBRAFV600EPredictiveSupportsSensitivity/ResponseBiliary Tract CancerTrametinib,DabrafenibZev A. Wainberg, 2019, Gastrointestinal Cancers Symposium, Abstract 187
BBRAFV600PredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,Cetuximab,IrinotecanScott Kopetz, 2017, ASCO Annual Meeting, Abstract 3505
DBRAFG466VPredictiveSupportsSensitivity/ResponseColorectal CancerIrinotecan,PanitumumabYao et al., 2017
DBRAFG466VPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerVemurafenibYao et al., 2017
DBRAFG466VPredictiveDoes Not SupportSensitivity/ResponseSolid TumorVemurafenibYao et al., 2017
DBRAFD594GPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibYao et al., 2017
DBRAFL525RFunctionalSupportsGain of FunctionShinozaki et al., 2017
CBRAFV600DPredictiveSupportsSensitivity/ResponseMelanomaBRAF InhibitorMenzer et al., 2019
CBRAFV600DPredictiveSupportsSensitivity/ResponseMelanomaMitogen-Activated Protein Kinase Kinase Inhibitor,BRAF InhibitorMenzer et al., 2019
CBRAFV600_K601>EPredictiveSupportsSensitivity/ResponseMelanomaMitogen-Activated Protein Kinase Kinase Inhibitor,BRAF InhibitorMenzer et al., 2019
BBRAFG469PredictiveSupportsSensitivity/ResponseMelanomaBRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase InhibitorMenzer et al., 2019
CBRAFA598VPredictiveDoes Not SupportSensitivity/ResponseMelanomaBRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase InhibitorMenzer et al., 2019
CBRAFN486_P490delPredictiveSupportsSensitivity/ResponsePancreatic CancerTrametinibAguirre et al., 2018
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,Irinotecan,CetuximabYang et al., 2012
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,ErlotinibYang et al., 2012
DBRAFG463EOncogenicSupportsOncogenicityCancerWan et al., 2004
CBRAFT599dupPredictiveSupportsSensitivity/ResponseGangliogliomaTrametinib,DabrafenibMiller et al., 2021
BBRAFV600E OR BRAF K601EPredictiveSupportsSensitivity/ResponseColorectal CancerCobimetinib,VemurafenibKlute et al., 2022
BBRAFV600EPredictiveSupportsSensitivity/ResponseCancerDabrafenib,TrametinibSalama et al., 2020
BBRAFV600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 MutationPredictiveDoes Not SupportSensitivity/ResponseCancerSelumetinibEckstein et al., 2022
BBRAFV600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Inactivating MutationPredictiveDoes Not SupportSensitivity/ResponseCancerSelumetinibEckstein et al., 2022
BBRAFV600EPredictiveSupportsSensitivity/ResponseLow Grade GliomaVemurafenibNicolaides et al., 2020
BBRAFV600EPrognosticDoes Not SupportPoor OutcomeMelanomaMeckbach et al., 2014
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenibYang et al., 2012
CBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaPictilisibSarker et al., 2015
BBRAFV600EPredictiveDoes Not SupportResistanceMelanomaMEK Inhibitor RO4987655Zimmer et al., 2014
BBRAFWildtypePredictiveDoes Not SupportResistanceMelanomaMEK Inhibitor RO4987655Zimmer et al., 2014
CBRAFV600PredictiveSupportsResistanceMelanomaRefametinibWeekes et al., 2013
DBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaDactolisib,SelumetinibPenna et al., 2016
BBRAFV600PredictiveSupportsSensitivity/ResponseColorectal CancerTrametinib,DabrafenibCorcoran et al., 2015
DBRAFL597RPredictiveSupportsSensitivity/ResponseSkin MelanomaVemurafenib,TrametinibDahlman et al., 2012
DBRAFL597SPredictiveSupportsSensitivity/ResponseSkin MelanomaVemurafenib,TrametinibDahlman et al., 2012
DBRAFL597QPredictiveSupportsSensitivity/ResponseSkin MelanomaTrametinib,VemurafenibDahlman et al., 2012
BBRAFD594GPrognosticSupportsPoor OutcomeColorectal CancerAmaki-Takao et al., 2016
BBRAFV600EPredictiveSupportsSensitivity/ResponseHairy Cell LeukemiaVemurafenibTiacci et al., 2015
CBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,PanitumumabPietrantonio et al., 2016
BBRAFV600PredictiveDoes Not SupportSensitivity/ResponseColorectal CancerCetuximab,VemurafenibHyman et al., 2015
CBRAFV600EPredictiveSupportsSensitivity/ResponseMultiple MyelomaVemurafenibSharman et al., 2014
DBRAFMutationPredictiveSupportsResistanceColorectal CancerCetuximabBertotti et al., 2011
DBRAFG596CPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDabrafenib,TrametinibNoeparast et al., 2017
CBRAFV600E AND GNAS R201CPredictiveSupportsResistanceColorectal CancerIrinotecan,Vemurafenib,CetuximabHong et al., 2016
CBRAFV600EPrognosticDoes Not SupportPoor OutcomeColorectal CancerHe et al., 2009
BBRAFV600KPredictiveSupportsSensitivity/ResponseMelanomaTrametinibFlaherty et al., 2012
DBRAFV600E AND KRAS G12DPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
CBRAFExon 15 MutationPredictiveDoes Not SupportSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib AnhydrousBen-Ami et al., 2016
CBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenibHainsworth et al., 2018
CBRAFG464VPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFG469APredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFG496APredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
Page 4 of 5
PreviousNext